Neurocrine Biosciences (NBIX) Non-Current Assets (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Non-Current Assets for 17 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 73.83% year-over-year to $3.7 billion; the trailing twelve-month figure through Jun 2026 stood at $10.4 billion (up 32.7% YoY), and the FY2025 full-year result was $2.1 billion, up 5.76% from the prior year.
• Non-Current Assets grew to $3.7 billion in Q2 2026 per NBIX's latest filing, from $2.5 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $3.7 billion in Q2 2026 and bottomed at $915.2 million in Q4 2022.
• Historically, Non-Current Assets has averaged $1.7 billion across 5 years, with a median of $1.7 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets declined 17.7% in 2023, then surged 80.52% in 2024.
• Over 5 years, Non-Current Assets stood at $915.2 million in 2022, then jumped by 79.68% to $1.6 billion in 2023, then grew by 21.26% to $2.0 billion in 2024, then advanced by 5.76% to $2.1 billion in 2025, then soared by 76.48% to $3.7 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $3.7 billion, $2.5 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.